Brand Drift | MedicinMan | Vivek Hattangadi
Brand Drift | MedicinMan | Vivek Hattangadi
Tuesday, September 1, 2026
28.6
C
Bengaluru
Hot topics
Lifetime Value of a Patient: Why Indian Pharma must Transition from Product-centric Selling to Patient-centric Healthcare
Introduction
For decades, the Indian pharmaceutical industry has measured success...
DeepSeek – A Precursor to Patent Disruption?
The rise of open-source platforms, such as China’s DeepSeek...
Brecht Vanneste has been appointed as Managing Director of MSD India
He steps into the role with a clear mandate...
IQVIAÂ Sponsors Race for 7 to Commemorate World Rare Disease Day
“IQVIA is delighted to be associated for the fourth consecutive year as the main sponsor of Race for 7. While rare diseases, by virtue of their definition, affect relatively fewer number of patients, the overall number of rare disease patients is large enough to warrant more focused attention."
Novo Nordisk’s Big Reset: What 9,000 Job Cuts Signal for Pharma’s Future
For years, Novo Nordisk was the poster child of growth. Its GLP-1 drugs, Ozempic and Wegovy, didn’t just change obesity treatment — they reshaped the company’s balance sheet. Demand outpaced supply, public awareness skyrocketed, and Novo’s market cap surged.
But growth always attracts challengers. Enter Eli Lilly with Mounjaro and Zepbound, and a wave of competitors and compounded generics threatening margins. Add in slowing sales growth and operational bloat from years of expansion, and suddenly Novo’s leadership had to answer tough questions about sustainability.
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Hot topics
The Strait of Hormuz—Why Geopolitics Is Now Core to India’s Healthcare Strategy
"Those who cannot remember the past are condemned to...
DiME (Digi MarketEr):-TiME to SHiNE
The new sparkling DIME (Digi MarketEr) are the ones who embrace digital transformation with open arms and voraciously feed on data analytics to satisfy their performance outcomes with an informed business decision. The benefit of being DIME is that it propels data management out of the hands of individual stakeholders, and puts data sets with insights on to center glass table (Transparent workplace) for informed decision making.
Is Your Career Headed in the Right Direction?
Make Sure You're Moving in the Right Direction… Digital,...
Biocon Biologics Scores FDA Approval—A Biosimilar Shake-Up for Amgen, Patients, and Investors
Biocon Biologics secures FDA approval for Bosayaâ„¢ and Aukelsoâ„¢,...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
Newsletter
Get important news delivered directly to your inbox and stay connected!